On this page

Last reviewed: 29 September 2026. A peptide certificate of analysis (CoA) is evidence about a defined sample under stated test conditions. It is not automatic proof that every vial is identical, that a product is sterile or safe, or that it is legally approved for human use.

Direct answer: read a peptide CoA in this order: sample identity → traceability → laboratory → method → result → specification → scope limits. A large HPLC area percentage answers a narrower question than most marketing claims imply. Identity, chromatographic composition, content, sterility, endotoxin, stability and chain of custody require different evidence.

The 60-second CoA screen

Check What should be visible? Red flag
1. Sample Specific name, form, sample or report ID and lot/batch reference Generic compound name with no unique sample link
2. Laboratory Verifiable legal name and independently confirmed contact details Logo only, anonymous analyst or contact details controlled by the seller
3. Dates Received, tested and reported dates in a plausible sequence Missing dates, future dates or reused report dates
4. Method Named method plus enough conditions or a controlled method identifier “HPLC passed” or “MS verified” with no procedure reference
5. Result Value, units and calculation basis linked to the stated method Percentage with no explanation of what the denominator represents
6. Specification Predefined acceptance criterion and its source “Pass” without a disclosed limit
7. Raw evidence Matching chromatogram, spectrum or report attachment where relevant Attachment identifiers do not match the certificate
8. Scope A conclusion limited to the submitted sample and tests performed Claims about sterility, clinical safety or all batches from HPLC alone

What a certificate of analysis actually is

A CoA records analytical work performed on a specified sample. A useful report connects the sample to a laboratory, one or more procedures, observable results, predefined acceptance criteria and an authorised report version. Its strength depends on that complete chain—not on the document title or a prominent percentage.

For Australian readers, laboratory accreditation can support confidence in technical competence, but it must be checked at the level of the organisation and the relevant testing scope. The National Association of Testing Authorities (NATA) explains that ISO/IEC 17025 accreditation supports confidence in the validity and reliability of testing, calibration, sampling and measurement results. Accreditation in one field does not mean every test a laboratory offers is within its accredited scope.

Important boundary: even a technically sound CoA does not turn an unapproved therapeutic good into an ARTG-included medicine. Laboratory evidence, manufacturing authorisation, regulatory approval and clinical evidence are separate questions.

TGA release-CoA field check

For a finished product released for supply, TGA guidance describes a CoA as a certified statement for one manufactured batch and lists: manufacturer; product name; batch number; manufacture, test and certificate dates; each test; each result; acceptance criteria; method references; and the appropriate company official’s signature.

Scope note: that guidance applies to regulated finished-product quality systems. A seller-provided research report should not borrow the regulatory meaning of “release for supply” unless the surrounding manufacturing and regulatory requirements actually apply.

Start with traceability—not the purity number

Before interpreting any analytical result, ask whether the certificate can be connected to the material it claims to describe.

  • Report identity: unique report number, page count, version and amendment history.
  • Sample identity: submitted name, physical form, sample ID and any manufacturer or sponsor information actually provided to the laboratory.
  • Lot connection: lot or batch reference that can be matched to controlled records—not simply repeated in marketing copy.
  • Receipt record: date received, condition on receipt, seal status and any sample discrepancy noted by the laboratory.
  • Custody: who selected, submitted, transported and stored the sample.
  • Report authority: authorisation, signature or electronic approval and the responsible laboratory entity.

If a seller selected and mailed the sample without an independent sampling plan or controlled chain of custody, the report may accurately describe that submitted sample while saying little about other units sold under the same label. A batch number printed on both documents is useful, but it is not a complete custody record.

Match every test to the question it can answer

Report element Question it can help answer What it does not establish by itself
HPLC area percentage How detector response was distributed among included chromatographic peaks under the stated conditions Total mass, sequence identity, potency, sterility or clinical safety
Mass spectrum / LC–MS Whether observed mass-to-charge data support the expected molecular mass or identity Complete impurity control, content, sterility or equivalence to an authorised medicine
Assay or content Amount of target analyte relative to a suitable standard and calculation procedure Representative sampling of every unit or clinical suitability
Water / volatile content Moisture or volatile fraction under the specified procedure Identity, microbiological quality or stability through shelf life
Sterility test Whether viable microorganisms were detected in the tested units under the stated method An absolute guarantee for every unit or absence of endotoxin
Endotoxin test Bacterial endotoxin response against a defined limit Sterility, identity or absence of other contaminants
Stability study How defined quality attributes changed over time under controlled conditions Shelf life under untested containers, temperatures or handling conditions

Why “99% HPLC purity” is often misunderstood

Many peptide reports use area normalisation: the nominated peak area is divided by the total area of included peaks detected under one chromatographic method. This can be useful for comparing chromatographic composition, but it is not the same as saying that 99% of the vial’s mass is the intended peptide.

The number can be affected by detector response, co-elution, wavelength, sample preparation, baseline selection, integration rules, omitted peaks and substances that are weakly detected or not detected by that method. Water, salts, counter-ions, residual solvents and non-UV-responsive material may require separate measurements.

Translation: “99% main-peak area” should be reported as exactly that. Rewriting it as “99% pure, correctly dosed, sterile and safe” combines several claims that the chromatogram did not test.

Read the method—not merely the instrument name

“HPLC” and “mass spectrometry” name analytical technologies, not complete procedures. ICH Q2(R2) treats validation as evidence that an analytical procedure is fit for its intended purpose. Relevant performance characteristics can include specificity or selectivity, accuracy, precision, range, robustness and suitable detection or quantitation limits, depending on the procedure’s purpose.

A report does not need to reproduce an entire laboratory standard operating procedure, but it should provide a controlled method identifier or enough information to interpret the result. For chromatography that may include column, mobile phases, gradient, flow, detector and wavelength, sample preparation, reference material, system suitability and calculation basis. Identity, impurity and quantitative procedures answer different questions and need different supporting evidence.

Result, specification and “pass” are three different things

  1. Result: the value observed for the tested sample.
  2. Specification: the predefined acceptance criterion.
  3. Decision: whether the result meets that criterion under the stated rule.

A result can be numerically precise while the specification is unsuitable or unexplained. A “pass” statement is not independently interpretable when the criterion, method and basis for the limit are hidden. Client-supplied, internal, pharmacopoeial and regulatory specifications are not automatically equivalent; the report should identify the applicable basis.

Verify the laboratory and the accreditation scope

Do not verify a laboratory only through the phone number, QR code or web address printed on the certificate. Use an independent directory or the laboratory’s independently located website. In Australia, search NATA’s accredited-organisation directory, open the organisation record and inspect the published scope for the relevant activity.

A genuine accreditation symbol is not a universal approval badge. Check:

  • whether the named legal entity and location match;
  • whether accreditation was current on the report date;
  • whether the specific test or technical field appears within scope;
  • whether the report marks results produced outside the accredited scope;
  • whether subcontracted testing is identified; and
  • whether an amended report replaces an earlier version.

An annotated CoA anatomy

Zone What to inspect Question to ask
A · Header Laboratory entity, address, report ID, page count and accreditation marks Can I verify the issuer independently?
B · Sample Sample ID, name, form, lot, submitter and receipt condition What physical material does this report actually follow?
C · Methods Procedure IDs, instruments, standards, preparation and test dates Were the methods fit for the claimed purpose?
D · Results Values, units, uncertainty where relevant, specifications and pass/fail rules Is each conclusion narrower than or equal to the evidence?
E · Attachments Chromatogram, spectra, integration table and matching identifiers Do the raw-evidence labels match the certificate?
F · Authorisation Approver, report date, electronic controls and amendment statement Is this the current authorised version?

Interactive red-flag review

Open each section while reviewing a report. These are investigation prompts, not a numerical product-safety score.

Identity and traceability
  • The report has no unique sample or report identifier.
  • The lot number is absent, generic or inconsistent across pages.
  • The sample description changes between the certificate and attachments.
  • No receipt condition, submitter or custody information is available.
Methods and calculations
  • Only an instrument name is supplied.
  • The report does not distinguish area percentage from quantitative assay.
  • No reference material, system-suitability information or controlled method identifier is visible.
  • Units or calculation bases change without explanation.
Claims that exceed the tests
  • HPLC is used to claim sterility, content and clinical safety.
  • A mass match is presented as proof of full purity.
  • One sample result is promoted as proof for every batch or future unit.
  • A CoA is described as evidence of TGA approval or lawful therapeutic supply.
Document authenticity
  • The issuing laboratory cannot be found independently.
  • QR codes or verification links resolve only to a seller-controlled page.
  • Signatures, dates, fonts or identifiers are internally inconsistent.
  • The laboratory will not confirm the report number or authorised version.

A worked interpretation example

Suppose a hypothetical report states “HPLC purity: 99.2%; pass” and includes a mass spectrum consistent with the expected molecular mass. A defensible interpretation is:

The submitted sample produced a nominated chromatographic main-peak area of 99.2% under the stated HPLC method, and the reported mass data were consistent with the expected molecular mass. The report may support chromatographic composition and identity for that sample. It does not, without separate evidence, establish peptide content per container, representative sampling, sterility, endotoxin control, stability, manufacturing compliance, clinical safety or regulatory approval.

This language is less dramatic than a marketing claim, but it is more scientifically useful because it preserves the boundary of each measurement.

What a CoA cannot prove by itself

  • that the tested sample represents every unit in a lot;
  • who manufactured the material or under which quality system;
  • the complete storage and transport history;
  • equivalence to a product used in a published clinical trial;
  • clinical effectiveness, safety or suitability for a person;
  • Australian ARTG inclusion, lawful advertising or lawful supply; or
  • a shelf life that was not supported by a suitable stability programme.

Printable review checklist

  1. Record the report number, version and page count.
  2. Match the sample ID and lot across every page and attachment.
  3. Verify the laboratory independently.
  4. Check accreditation status and the relevant scope.
  5. List each method and the exact question it answers.
  6. Copy each result with its units and calculation basis.
  7. Copy the acceptance criterion and identify its source.
  8. Separate identity, area purity, assay, sterility, endotoxin and stability.
  9. Document who selected and submitted the sample.
  10. Write one sentence stating what remains untested.

Safe conclusion template: “This report supports [specific finding] for [specific sample] under [named method and date]. It does not establish [important untested questions].”

Primary standards and official references

  1. TGA: finished-product specifications and certificate-of-analysis fields
  2. ICH Q2(R2): Validation of Analytical Procedures
  3. NATA: ISO/IEC 17025 testing and calibration accreditation
  4. NATA: Search accredited organisations and scopes
  5. NATA: Test reports explained
  6. TGA: Responsibilities for unapproved peptide products
Editorial scope: This guide does not authenticate a particular report, laboratory or product and is not medical, legal or procurement advice. It provides a method for interpreting analytical evidence and its limits.
Citation record

How to cite this article

How to Read a Peptide Certificate of Analysis: A Field-by-Field Guide. Elite Peps Australia. Published 2 July 2026; updated 8 October 2026. https://elitepepsaustralia.com/how-to-read-a-peptide-lab-report/

Source checks: Consult the primary studies, trial records and regulator documents linked in this article for current evidence and status. Publication and update dates do not by themselves indicate an evidence review.